BHCM
JAZZ icon

Brevan Howard Capital Management’s Jazz Pharmaceuticals JAZZ Stock Holding History

Brevan Howard Capital Management’s Portfolio JAZZ Stock Details JAZZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-21,597
Closed -$2.41M – 1241
2024
Q3 		$2.41M Buy
21,597
+7,723
+56% +$846K 0.02% 239
2024
Q2 		$1.48M Buy
13,874
+9,768
+238% +$1.07M 0.01% 265
2024
Q1 		$494K Sell
4,106
-8,450
-67% -$1.04M ﹤0.01% 471
2023
Q4 		$1.54M Buy
+12,556
New +$1.57M 0.02% 156

Other funds holding JAZZ

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return
Pacer Advisors
Pacer Advisors Malvern, Pennsylvania $35.6B AUM 18.19% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Brevan Howard Capital Management's JAZZ Position: Q4 2024 in Review

Brevan Howard Capital Management sold out of Jazz Pharmaceuticals (JAZZ) in Q4 2024, closing a stake of 21,597 shares — an estimated $2.41M sold.

Brevan Howard Capital Management first reported a position in JAZZ in Q4 2023 and held it in 4 quarters. The position peaked at $2.41M in Q3 2024. 508 funds tracked by Wall St. Rank hold JAZZ as of Q4 2024.

  • Brevan Howard Capital Management reported no remaining Jazz Pharmaceuticals position as of Q4 2024 after selling out during the quarter.
  • Brevan Howard Capital Management sold 21,597 Jazz Pharmaceuticals shares in Q4 2024, an estimated $2.41M.
  • Brevan Howard Capital Management first reported a position in Jazz Pharmaceuticals in Q4 2023 and held it in 4 quarters.
  • Brevan Howard Capital Management's Jazz Pharmaceuticals position peaked at $2.41M in Q3 2024.
  • 508 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q4 2024.

Based on Brevan Howard Capital Management's 13F filing for Q4 2024, filed 14 Feb 2025.